Angiochem PDC maybe a great example for TH1902
https://pubmed.ncbi.nlm.nih.gov/22203732/
Angiochem PDC, GRN1005 is a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide, angiopep-2, that targets the low-density lipoprotein receptor-related protein 1 (LRP-1).
They conducted PhI trial in 2007 and finished it in 2010. In the trial, does escalation study was initiated until MTD is defined. Interestingly, tumor size shrinkage was observed in part of patients after three cycles treatment (1 cycle = 3 three weeks). Other patients had stable disease for multiple months.
From my point of view, the path adead of TH1902 is similar to that of Angiochem's PDC. Hope TH is able to show the effectiveness of TH1902 as Angiochem achieved for GRN1005.